We evaluated the effects of supplementation with oral l-glutamine in Walker-256 tumor-bearing rats. A total of 32 male Wistar rats aged 54 days were randomly divided into four groups: rats without Walker-256 tumor, that is, control rats (C group); control rats supplemented with l-glutamine (CG group); Walker-256 tumor rats without l-glutamine supplementation (WT group); and WT rats supplemented with l-glutamine (WTG group). l-Glutamine was incorporated into standard food at a proportion of 2 g/100 g (2%). After 10 days of the experimental period, the jejunum and duodenum were removed and processed. Protein expression levels of key enzymes of gluconeogenesis, that is, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, were analyzed by western blot and immunohistochemical techniques. In addition, plasma corticosterone, glucose, insulin, and urea levels were evaluated. The WTG group showed significantly increased plasma glucose and insulin levels (p < 0.05); however, plasma corticosterone and urea remained unchanged. Moreover, the WTG group showed increased immunoreactive staining for jejunal phosphoenolpyruvate carboxykinase and increased expression of duodenal glucose-6-phosphatase. Furthermore, the WTG group presented with less intense cancer cachexia and slower tumor growth. These results could be attributed, at least partly, to increased intestinal gluconeogenesis and insulinemia, and better glycemia maintenance during fasting in Walker-256 tumor rats on a diet supplemented with l-glutamine.
Introduction
One of the most marked negative effects of cancer is cachexia, a complex syndrome characterized by anorexia, and increased proteolysis with loss of muscle and adipose mass. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The prevalence of cachexia in gastric, pancreatic, lung, advanced colorectal, or prostate neoplasias is more than 50%, whereas it is estimated to be between 30% and 50% in non-Hodgkin lymphoma, breast cancer, sarcomas, and leukemias. 11 Moreover, a cachectic status worsens the prognosis and implies increased mortality, being responsible for the death of 22% of cancer patients. [12] [13] [14] The development of cachexia in cancer depends upon signaling promoted by both tumor and host tissues, resulting in the stimulation of catabolic pathways and inhibition of metabolic pathways. 8, 12 Cachexia can dramatically affect the small intestine, resulting in failures of glucose and l-glutamine homeostasis, cell proliferation, and intestinal absorption. 13 The small intestine has a crucial role in glucose homeostasis [14] [15] [16] [17] [18] [19] [20] due to the expression of key enzymes of gluconeogenesis, that is, glucose-6-phosphatase (G6Pase) [21] [22] [23] and phosphoenolpyruvate carboxykinase (PEPCK). [24] [25] [26] [27] [28] [29] Furthermore, the small intestine controls food intake, as well as the release of glucose into the portal circulation and the reduction of food intake induced by hyperproteic diets or gastric bypass surgery. 17 l-Glutamine is an amino acid that plays an essential role as the main intestinal fuel. In addition, l-glutamine participates in other functions of the renal, neuronal, pancreatic, and immune systems. 30 This amino acid is a precursor of intestinal gluconeogenesis during prolonged fasting when liver gluconeogenesis becomes reduced. 22 Furthermore, l-glutamine is an important precursor of peptides, proteins, and carbohydrates, as well as purines and pyrimidines that are essential for the synthesis of nucleic acids and nucleotides. 30, 31 In addition, l-glutamine has a central role in preventing oxidative stress due to its importance in the formation of l-glutathione, a powerful antioxidant involved in neuroprotection. In the intestinal mucosa, l-glutamine acts as the main source of energy for cell migration and proliferation. 32, 33 Although cancer cells are avid glutamine consumers, the nutritional support supplied by l-glutamine added to the diet improves clinical responses in cancer patients. 31 Such clinical improvements are consistent with a role for l-glutamine in stimulating immune function and augmenting protein synthesis in skeletal muscle. 30 In agreement with these clinical studies, we previously demonstrated that glutamine supplementation restored the proliferation of intestinal mucosa in Walker-256 tumor-bearing (WT) rats. 33 Here, we have expanded this previous study investigating the effect of glutamine supplementation on intestinal gluconeogenesis, cachexia index, blood corticosteronemia, glycemia, insulinemia, and uremia in WT rats.
Methods

Animal model of cachexia and supplementation with l-glutamine
All procedures were performed in accordance with the ethical principles adopted by the Brazilian Society for Laboratory Animal Science and were approved by the Ethics Committee for Animal Experimentation of the State University of Maringá (protocol number: 099/2012).
A total of 32 male Wistar rats (Rattus norvegicus) aged 54 days were randomly divided into four groups: rats without a WT, that is, control rats (C group); control rats supplemented with l-glutamine (CG group); rats with a WT (WT group); and WT rats supplemented with l-glutamine (WTG group).
The rats were kept in individual cages for the experimental period (10 days), with a 12-h dark/12-h light cycle and a controlled temperature (24°C). Food and water were available ad libitum. The non-supplemented animals (C and WT groups) received standard chow (Nuvilab, Colombo, Brazil), whereas the supplemented rats (CG and WTG groups) received l-glutamine (Fagron of Brazil Pharma Ltda, São Paulo, Brazil) incorporated in the standard chow at a proportion of 2 g/100 g. 32 Walker-256 tumors were induced according to the methodology described by Guarnier et al. 10 by subcutaneously inoculating 8.0 × 10 7 viable tumor cells in 0.5 mL phosphate-buffered saline (PBS), 16.5 mM PBS, 137 mM NaCl, and 2.7 mM KCl, pH 7.4/animal in the right rear flank. The groups without tumors (C and CG groups) received the same volume of PBS inoculated in the same location.
After the experimental period, all rats were fasted for 48 h, weighed, and anesthetized with an intraperitoneal (40 mg/kg) injection of sodium thiopental (Abbott Laboratories, Chicago, IL, USA). Body weights and food intake (24 h) of rats were measured before fasting.
Calculation of cachexia index
After an animal's death, each tumor was carefully dissected and weighed, and the percentage of body weight loss was calculated according to the equation below. The animals were considered cachectic when the body mass loss was greater than 10% according to Guarnier et al. 10 Body mass loss % = ibm-fbm+ tm +mgcg
where ibm refers to initial body mass of the WT rat, fbm refers to final body mass of the WT rat, tm refers to tumor mass, and mgcg refers to mass gain of the control group.
Plasma concentration of corticosterone, glucose, insulin, and urea
Blood was collected by cardiac puncture, and plasma was obtained by using potassium fluoride as an anticoagulant (Laborclin, Pinhais, Brazil) for the determination of glucose, corticosterone, insulin, and urea concentrations. The following kits were used: corticosterone EIA kit (ADI-900-097; Enzo Life Sciences GmbH, Lorrach, Germany) and DetectX urea nitrogen detection kit (K024-H1; Arbor Assays, Ann Arbor, MI, USA). Insulin was measured by radioimmunoassay (Wizard2 Automatic Gamma Counter, TM-2470; PerkinElmer ® , Shelton, CT, USA). Human insulin, monoclonal anti-insulin antibody from rats (I2018; Sigma-Aldrich, St Louis, MO, USA) and 125 I-labeled recombinant human insulin (NEX420010UC; PerkinElmer) were used. The limit of detection was 0.006 ng/mL. 34 Blood glucose was measured using a glucose oxidase technique. 35 
Western blot for G6Pase and PEPCK
After a celiotomy, the duodenum and the jejunum were removed and gently washed with Krebs-Ringer buffer solution pH 7.4. Then, the homogenates were prepared, and total proteins of the duodenum and jejunum mucosal were isolated after centrifugation at 10,000g for 10 min in homogenization buffer (50 mM Tris-HCl, 600 mM NaCl, 1 mM EDTA (ethylenediaminetetraacetic acid), and 1% protease inhibitor solution, pH 7.4), and total protein concentration was determined by the method of Bradford. 36 Samples were then cut in semi-serial 10-µm-thick sections in a cryostat microtome, arranged on previously prepared slides with 2% organosilane adhesive in acetone, and stored at −18°C. For immunohistochemical analysis, sections at room temperature were washed three times in a solution containing 0.5% Triton X-100 (Sigma-Aldrich) in 0.1 M PBS, pH 7.4, and blocked for 6 h in solution containing 2% bovine serum albumin (BSA; Sigma-Aldrich), 0.5% Triton X-100, and 10% goat serum in 0.1 M PBS, pH 7.4. The immunostaining was performed in different blades. Sections were then incubated in a humidified chamber with a solution containing the following primary antibodies: rabbit polyclonal anti-G6Pase at a dilution of 1:1000 (sc-25840; Santa Cruz Biotechnology) or rabbit polyclonal anti-PEPCK at a dilution 1:1000 (sc-32879; Santa Cruz Biotechnology), diluted in 2% BSA solution containing Triton X-100 and 0.5% goat serum in 0.1 M PBS, pH 7.4, for 48 h at 4°C. After incubation, sections were washed three times with a solution containing Triton X-100 in 0.1 M PBS, pH 7.4. The sections were incubated in a dark humid chamber, in solution containing polyclonal goat anti-rabbit IgG secondary antibody 1:1000 (A-11011, Alexa Fluor ® 568; Molecular Probes, Invitrogen Co., Carlsbad, CA, USA), 2% BSA solution, Triton X-100, and 0.5% goat serum in 0.1 M PBS, pH 7.4, for 48 h at 4°C. Sections were then washed with a solution containing Triton X-100 and 0.5% goat serum in 0.1 M PBS, pH 7.4, and mounted on slides with 10% PBS in glycerol. 
Analysis of immunostaining for G6Pase and PEPCK
Statistical analysis
Results were statistically analyzed using Statistica 8.1 and GraphPad Prism 6.1 software, and expressed as mean ± standard error of the mean (SEM). For quantitative data, we performed one-way analysis of variance (ANOVA), followed by Fisher's post-test. For the analysis of cachexia and tumor mass index, data were analyzed using Student's t test. The significance level was 5%.
Results
Body weight gain (Table 1) was similar (p = 0.978) in the C and CG groups, whereas the body mass was significantly reduced (p < 0.0001) in the WT group compared with C and CG groups. l-Glutamine supplementation significantly decreased (61%; p = 0.026) body weight loss in the WTG group compared with the WT group. However, food intake (Table 1 ) did not differ among groups (WTG vs WT vs C vs CG).
The WTG group exhibited a lower (76%; p = 0.023; Figure 1 (a)) tumor growth mass and lower (p = 0.014; Figure 1 (b)) cachexia index (WTG group vs WT group).
Plasma concentration of corticosterone, glucose, insulin, and urea
The plasma concentrations of corticosterone and urea did not exhibit a significant difference (p > 0.05) between C, CG, WT, and WTG groups ( Table 2) .
Insulin levels in the WTG group compared with the WT group were significantly increased (49%; p = 0.044; Table 2 ). However, there were no significant differences (p > 0.05; Table 2 ) between C, CG, and WT groups. In addition, the WTG group showed significantly increased (13%, p = 0.019; Table 2 ) glycemia when compared with the WT group. On the contrary, C, CG, and WT groups showed similar (p > 0.05; Table 2 ) glycemia.
Western blot
The migration of β-actin, G6Pase, and PEPCK proteins in duodenum and jejunum samples is shown in Figures 2  and 3 , with their molecular weights of 42, 36, and 62 kDa, respectively. Results are expressed as mean ± SEM (n = 8 animals per group). Significant differences between means were analyzed by one-way ANOVA test followed by Fisher's post-test for multiple comparisons, *p < 0.05 versus C; #p < 0.05 versus WT. Rats without Walker-256 tumor (WT), that is, control rats (C group); control rats supplemented with 2% l-glutamine (CG group); rats with WT (WT group); and WT rats supplemented with 2% l-glutamine (WTG group). The level of G6Pase expression (C group vs CG group) was not significantly different in the duodenum (p = 0.875; Figure 2(a) ) and the jejunum (p = 0.289; Figure 3(a) ). WT rats showed a marked increase (122%; p = 0.025; Figure  2 (a)) in the expression of duodenal G6Pase (WT group vs C group). In contrast, WT rats showed a substantial reduction (78%; p < 0.0001; Figure 3 (a)) in the expression of jejunal G6Pase (WT group vs C group).
l-Glutamine supplementation in control rats (CG group) promoted a significant decrease (22%; p = 0.006; Figure 2 (b)) and increase (48%; p = 0.008; Figure 3(b) ) in the duodenal and jejunal expression of PEPCK, respectively (C group vs CG group). Furthermore, the WT group showed a significant increase in PEPCK expression (C group vs WT group) in the duodenum (24%; p = 0.003; Figure 2 (b)) and jejunum (65%; p = 0.0005; Figure 3(b) ). However, l-glutamine supplementation (WTG group vs WT group) did not influence PEPCK expression in the duodenum (p = 0.299; Figure 2 (b)) and jejunum (p = 0.350; Figure 3(b) ).
Immunoreactive intensity of G6Pase and PEPCK in histological sections
A similar intensity of immunoreactive G6Pase (IR-G6Pase) was observed in tissues of C and CG groups, either in the duodenum (p = 0.456; Figure 2 (c)) or in the jejunum (p = 0.082; Figure 3(c) ). A similar level of IR-G6Pase was also observed (WTG group vs WT group) in the duodenum (p = 0.372; Figure 2 (c)) and jejunum (p = 0.721; Figure 3(c) ).
The WT group exhibited a significant increase (50%; p < 0.0001; Figure 2 (c)) in duodenal IR-G6Pase (WT group vs C group). In contrast, we observed a significant reduction (52%; p < 0.0001; Figure 3 (c)) in jejunal IR-G6Pase (WT group vs C group).
Glutamine supplementation promoted a significant reduction (13%; p = 0.013; Figure 2(d) ) of duodenal IR-PEPCK and its marked increase in the jejunum (92%; p < 0.0001; Figure 3(d) ) when comparing C and CG groups. Furthermore, WT and WTG groups exhibited a similar level of (p = 0.580; Figure 2(d) ) IR-PEPCK in the duodenum. However, the WTG group showed a significantly higher (17%; p = 0.0002; Figure 3 
Discussion
The development of a cancer leads to a loss of energy balance in response to the intensification of catabolism, which, in turn, results in cancer-associated cachexia. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The lower cachexia index and reduced body weight loss in WTG rats compared to the WT group confirmed our previous studies demonstrating the beneficial effects of l-glutamine supplementation in the diet, particularly in the small intestine. 33, 37 These anti-cachectic effects could be attributed to the higher levels of l-glutamine available in the blood. This, in turn, would have led to an improvement in the antioxidant status of healthy cells in the small intestine by reestablishing their levels of l-glutamine, 13, 38 crucial in maintaining their digestive and absorptive capacities. 30, 31 Moreover, an improvement of the immune system occurs in response to l-glutamine via a reduction of tumor necrosis factor (TNF)-α, IL-1, and IL-6 levels. 38 Furthermore, l-glutamine prevents proteasomal degradation and apoptosis 34 and reduces hypoxia, 38 nitric oxide synthesis, and oxidative stress. 37, 39 Such effects may be considered positive and help explain the inhibition of tumor growth by l-glutamine.
The role of intestinal gluconeogenesis in the maintenance of glycemia during fasting is well established. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 40 The ability of the intestine to express G6Pase and PEPCK and respond to signaling molecules that regulate the gene expression of these enzymes has been described previously. 15, 18 Increased PEPCK (expression and IR-PEPCK) in the jejunum and duodenum of WT rats can be explained by the development of compensatory responses against the negative energy balance that occurs in cachectic animals (WT group vs C group). In such animals, substances released by the tumor promote the synthesis of glucose that supplies Results are expressed as mean ± SEM (n = 8 animals per group). Significant differences between means were analyzed by a one-way ANOVA test followed by Fisher's post-test for multiple comparisons, *p < 0.05 versus C; #p < 0.05 versus WT. Rats without a Walker-256 tumor (WT), that is, control rats (C group); control rats supplemented with 2% l-glutamine (CG group); rats with WT (WT group); and WT rats supplemented with 2% l-glutamine (WTG group). , that is, control rats (C group); control rats supplemented with 2% l-glutamine (CG group); rats with WT (WT group); and WT rats supplemented with 2% l-glutamine (WTG group). Results are expressed as mean ± standard error of the mean. Significant differences between means were analyzed by a one-way ANOVA test followed by Fisher's post-test for multiple comparisons, *p < 0.05 versus C; #p < 0.05 versus WT. Photomicrographs illustrate the immunoreactivity of duodenal G6Pase in tissues from (e) C, (f) CG, (g) WT, and (h) WTG groups. Photomicrographs reveal the immunoreactivity of duodenal PEPCK in tissues from (i) C, (j) CG, (k) WT, and (l) WTG groups. Calibration bar: 50 µm. , that is, control rats (C group); control rats supplemented with 2% l-glutamine (CG group); rats with WT (WT group); and WT rats supplemented with 2% l-glutamine (WTG group). Results are expressed as mean ± standard error of the mean. Significant differences between means were analyzed by a one-way ANOVA test followed by Fisher's post-test for multiple comparisons, *p < 0.05 versus C; #p < 0.05 versus WT. Photomicrographs illustrate the immunoreactivity of jejunal G6Pase in tissues from (e) C, (f) CG, (g) WT, and (h) WTG groups. Photomicrographs represent the immunoreactivity of jejunal PEPCK in tissues from (i) C, (j) CG, (k) WT, and (l) WTG groups. Calibration bar: 50 µm.
the high energy demand of the tumor. 41, 42 For example, according to Croset et al., 14 the intestinal synthesis of glucose from l-glutamine occurs because the small intestine expresses glutaminase. l-Glutamine supplementation promoted the increased expression of jejunal IR-PEPCK (WTG rats vs WT rats). In agreement with our results, Mithieux et al. 22 also observed the increased activity and expression of jejunal PEPCK compared to that in other segments. These results suggest an important role for l-glutamine in promoting gluconeogenesis, thereby supplying glucose as energy supply to healthy cells without affecting tumor growth.
In contrast to the jejunum, l-glutamine supplementation did not change the expression of PEPCK in the duodenum. In fact, the duodenum and jejunum exhibit different capacities to express and regulate the enzymatic activity of gluconeogenesis. 22 The higher glycemia observed in the WTG group in comparison with WT animals could be attributed to a metabolic adaptation of tumor cells to the higher availability of l-glutamine, leading to a lower glucose uptake as reported by Daye and Wellen. 43 The increased glycemia may also be related to increased gluconeogenesis activity in the small intestine due to the increased availability of glutamine as a glucose precursor. 22, 26, 44, 45 Our results are consistent with the higher expression of gluconeogenic enzymes found in the small intestine (G6Pase and PEPCK) of WT rats supplemented with l-glutamine.
WT rats supplemented with l-glutamine in their diet also showed higher insulinemia, probably as a consequence of increased glycemia. [46] [47] [48] This could be attributed to the stimulating effect of l-glutamine on insulin secretion, which is reduced in WT animals without supplementation with this amino acid. 49, 50 Furthermore, considering that insulin can inhibit Walker-256 tumor growth, 51 the beneficial effects of l-glutamine supplementation on slowing tumor growth in WTG rats could be attributed, at least in part, to the higher insulin levels measured in the WTG group. The mechanism by which insulin slows weight loss and inhibits cachexia associated with Walker-256 tumor growth could involve its classical effects in stimulating lipid and protein anabolism. 52 It follows that the antitumor activity of insulin may allow this hormone to be used in combination with chemotherapy to treat cancer. [53] [54] [55] Conclusion l-Glutamine supplementation of diet for 10 days in a cancer cachexia animal model promoted increased PEPCK expression in the jejunum that was associated with a significant elevation of glycemia and insulinemia, suggesting a beneficial effect on energy balance. An indirect effect on insulin secretion by l-glutamine is likely to prevent catabolism, thus reducing the harmful effects of cachexia.
